Weekly Wrap: Coronavirus Vaccine Developments and Tips for Turbulent Markets
We recap the week on Morningstar.com and note the most popular stocks, funds, and exchange-traded funds.
|Editor's note: Read the latest on how the coronavirus is rattling the markets and what investors can do to navigate it.|
How to Find Yield Without Getting Burned
Make sure to consider downside risk and volatility.
7 Undervalued Stocks With Healthy Yields
We expect these high yielders to sustain their dividends in the future. Plus, they're cheap.
How Did the Bucket Portfolios Stand Up to Market Turbulence?
High-quality bonds limited the mutual fund and ETF portfolios to modest losses in a tough first half.
Should You Pay Off Your Mortgage?
Retirees looking for a decent return in this low-rate climate would be wise to consider it.
Timeline Accelerates for COVID-19 Drug Development
Three new vaccines for coronavirus look poised for emergency use authorization in the U.S. this fall.
U.S. Fund Flows in June Cap a Wild First Half of 2020
Taxable-bond funds swing from historic carnage to record inflows.
Portfolio Planning and Personal Finance With Christine Benz
Is the '4% Rule' Broken?
Retirement researcher Wade Pfau discusses why low yields put this withdrawal rule at risk and what strategies retirees can use instead.
Should Your Portfolio Shift When the Economy Slumps?
How to make some upgrades during this down time.
Mutual Funds and Exchange-Traded Funds
June Analyst Ratings Upgrades, Downgrades, and More
Morningstar analysts rated 785 share classes and vehicles and 187 unique strategies in June 2020.
The 10 Biggest Fee Cuts of the Year
Some funds' fees are falling faster than others'.
ESG Investing Is About Long-Term Risk Management
Sustainable investing isn't just about values, it's about managing risks that affect all investors.
A Bold--and Exceptional--International Choice
Gold-rated Oakmark International can try the patience of investors--but it delivers over the long haul.
A Promising Quality Value ETF
This low-cost strategy carves an edge by targeting stocks with strong profitability and low valuations.
Pay-TV Troubles on Full View in Poor Start to 2020
Cord cutting is still an issue, but a subscriber death spiral remains unlikely.
2 Stocks We Find Attractive
Our analysts have their eyes on these companies.
A Quick Look at Amazon
Amazon's variety seems scattershot, but has a strategy behind it.
Stock Analyst Updates
Pfizer, BioNTech COVID-19 Vaccines Fast Tracked by FDA
We expect no-moat BioNTech and wide-moat Pfizer to move one of the test candidates into the next phase, planned to start as early as this month.
Pepsi’s Snack Business Helps It Navigate Marketplace
Sales came in at $15.9 billion for the quarter, a 3% year-over-year decline, for the wide-moat company.
In Q2, JPMorgan Again One of the Highest Quality Banks
As we’ve long pointed out, JPMorgan remains arguably one of the strongest and highest quality franchises under our coverage, and this showed in second-quarter results.
UnitedHealth Reports Strong Second Quarter
We are not making any changes to our 2020 outlook and fair value estimate for the narrow-moat company.
Wide-Moat J&J Posts Better-Than-Expected Q2
The company's drug group helps offset COVID-19 pressure on device sales.
Bank of America Books a Second Provisioning Charge
After incorporating these results into our forecast, and after incorporating a 50% probability of Joe Biden being elected and instituting his proposed tax hike, we are lowering our fair value estimate to $28 from $30.
Netflix Gains as Viewers Stay In; Sarandos Now Co-CEO
We are raising our FVE to $200 from $160 to account for the revenue impact of the larger subscriber base and slightly faster margin expansion than previously expected.
Why Private Equity Doesn't Belong in Defined-Contribution Plans
Contributor Scott Simon argues that private equity isn’t in any way a good thing for plan participants.
The Long View
Jamie Hopkins: How Low Bond Yields, Recession Impact Retirement Planning
A noted retirement specialist discusses the benefits and challenges of working longer, the virtues of Roth assets, and building retirement portfolios to last.
How to Approach Social Security During a Pandemic
Avoid an added layer of difficulty during this time by learning about your options.
What Advisors Need to Know About Learning Clients’ ESG Preferences
Research shows that investors can incorporate their ESG preferences and also earn strong returns.
Morningstar's Tax and IRA Guide
Strategies and investment ideas for lessening the tax bite.
Morningstar's Guide to the Development of a Coronavirus Vaccine
Here's how companies around the world are working toward a treatment.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.